Mersana Therapeutics Announces Poster Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Monday, October 23, 2017 8:01 PM UTC

CAMBRIDGE, Mass., Oct. 23, 2017 -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its proprietary Dolaflexin^® platform, today announced that it will report preclinical data on its second product candidate, XMT-1536, in a poster to be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutic, held October 26-30 in Philadelphia. Presentation details are as follows:

Title:			Relationship of NaPi2b expression and efficacy of XMT-1536, a NaPi2b targeting antibody-drug conjugate (ADC), in an unselected panel of human primary ovarian mouse xenograft models

Session:			Poster Session B, Therapeutic Agents: Biological

Presenter:			Rebecca Mosher, M.D., Executive Director, Translational Medicine

Date and Time:			Sunday, October 29, 2017, 12:30 p.m. - 4:00 p.m. ET

Poster/Abstract:			119/B119

About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana’s lead product candidate, XMT-1522, is in Phase I clinical trials in patients with advanced tumors expressing HER2, including breast cancer, non-small-cell-lung-cancer (NSCLC) and gastric cancer patients. The Company expects that its second product candidate, XMT-1536, will enter clinical trials in early 2018. In addition, multiple partners are using Mersana’s leading platform to advance their ADC pipelines.

Media Contact
Paul Kidwell
[email protected]
617-680-1088

Investors Contact
Stern Investor Relations, Inc.
Christina Tartaglia
[email protected]
(212) 362-1200

Editor's Picks

Breathing through your nose when you exercise may make your runs easier

Entrepreneurs are facing a mental health crisis — here's how to help them

Are fish oil supplements as healthy as we think? And is eating fish better?

Will AI kill our creativity? It could – if we don’t start to value and protect the traits that make us human

Does AI have a right to free speech? Only if it supports our right to free thought

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Why we need to set limits on sperm donation

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Seven techniques to avoid weight regain, approved by experts

Mersana Therapeutics Announces Poster Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Editor's Picks

Welcome to EconoTimes